ASH 2022 | The use of PET and ctDNA for risk stratification & to guide treatment decisions in Hodgkin lymphoma
Peter Borchmann
• 12 Dec 2022
Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, provides insight into emerging techniques to individualize and guide treatment for patients with Hodgkin lymphoma (HL), highlighting the advantages and disadvantages of PET-guided therapy and discussing the use of ctDNA measurable residual disease (MRD) detection. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
